Matthias Ritgen

16.3k total citations
120 papers, 3.9k citations indexed

About

Matthias Ritgen is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Matthias Ritgen has authored 120 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Genetics, 77 papers in Pathology and Forensic Medicine and 57 papers in Immunology. Recurrent topics in Matthias Ritgen's work include Chronic Lymphocytic Leukemia Research (98 papers), Lymphoma Diagnosis and Treatment (76 papers) and Immunodeficiency and Autoimmune Disorders (50 papers). Matthias Ritgen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (98 papers), Lymphoma Diagnosis and Treatment (76 papers) and Immunodeficiency and Autoimmune Disorders (50 papers). Matthias Ritgen collaborates with scholars based in Germany, Netherlands and United Kingdom. Matthias Ritgen's co-authors include Michael Kneba, Stephan Stilgenbauer, Michael Hallek, Monika Brüggemann, Sebastian Böttcher, Hartmut Döhner, Christiane Pott, Barbara Eichhorst, Thorsten Raff and Kirsten Fischer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Matthias Ritgen

112 papers receiving 3.8k citations

Peers

Countries citing papers authored by Matthias Ritgen

Since Specialization

Citations

This map shows the geographic impact of Matthias Ritgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Ritgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Ritgen more than expected).

Fields of papers citing papers by Matthias Ritgen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Ritgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Ritgen. The network helps show where Matthias Ritgen may publish in the future.

Co-authorship network of co-authors of Matthias Ritgen

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Ritgen. A scholar is included among the top collaborators of Matthias Ritgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Ritgen. Matthias Ritgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CLL-465 Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Julia von Tresckow, (unknown), Sandra Robrecht, Anna‐Maria Fink, Kirsten Fischer, Othman Al‐Sawaf, Moritz Fürstenau, Florian Simon, Nadine Kutsch, (unknown), Eugen Tausch, Matthias Ritgen, Sebastian Böttcher, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Petra Langerbeins, Barbara Eichhorst, Michael Hallek, Paula Cramer	0
2	MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR 2024 ·Methods in molecular biology ·Christiane Pott, Monika Brüggemann, Matthias Ritgen, Vincent H. J. van der Velden, Jacques J. M. van Dongen	0
3	Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax 2022 ·Clinical Cancer Research ·Moritz Fürstenau, Jonathan M. Weiss, (unknown), (unknown), Sandra Robrecht, Anna‐Maria Fink, Kirsten Fischer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Barbara Eichhorst, Michael Hallek, Paula Cramer	17
4	CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis 2022 ·Cancers ·Anke Schilhabel, (unknown), Paula Cramer, Julia von Tresckow, (unknown), Monika Szczepanowski, (unknown), Kirsten Fischer, Barbara Eichhorst, Sebastian Böttcher, Christof Schneider, Eugen Tausch, Monika Brüggemann, Michael Kneba, Michael Hallek, Matthias Ritgen	3
5	Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL 2022 ·Blood ·Paul J. Hengeveld, (unknown), (unknown), Frédéric Davi, François G. Kavelaars, Evert de Jonge, Sandra Robrecht, (unknown), (unknown), Matthias Ritgen, Peter E. Westerweel, Kirsten Fischer, Valentin Goede, Michael Hallek, Mark‐David Levin, Anton W. Langerak	12
6	Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial 2022 ·Leukemia ·Heiner Zimmermann, Christian Koenecke, Martin Dreyling, Christiane Pott, Ulrich Dührsen, D Hahn, Norbert Meidenbauer, Ingeborg A. Hauser, Mathias Rummel, Dominik Wolf‎, Michael Heuser, Christian Schmidt, Peter Schlattmann, Matthias Ritgen, Reiner Siebert, Ilske Oschlies, Ioannis Anagnostopoulos, Ralf Ulrich Trappe	15
7	Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry 2021 ·Annals of Hematology ·Heiner Zimmermann, Mirko Nitsche, Christiane Pott, Petra Reinke, Nina Babel, Robert Michael Hermann, Ingeborg A. Hauser, D Hahn, Matthias Ritgen, (unknown), Wolfram Klapper, Ioannis Anagnostopoulos, Ralf Ulrich Trappe, (unknown)	8
8	Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study 2021 ·Blood Advances ·Sebastian Böttcher, Robby Engelmann, Georgiana Grigore, Paula Fernández, Joana Caetano, Juan Flores‐Montero, Vincent H. J. van der Velden, Michaela Nováková, Jan Philippé, Matthias Ritgen, Leire Burgos, Quentin Lécrevisse, Sandra Lange, Tomáš Kalina, (unknown), (unknown), Jacques J. M. van Dongen, Carlos E. Pedreira, Alberto Órfão	14
9	CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial 2018 ·Blood ·Monika Szczepanowski, Johanna Richter, (unknown), Matthias Ritgen, Heiko Trautmann, Henrik Knecht, Mustafa Kondakci, Christoph Faul, Björn Steffen, Andreas Viardot, Michael Kneba, Dieter Hoelzer, Nicola Goekbuget, Monika Brüggemann	3
10	The GAIA (CLL13) trial – an international, randomized, four-arm study for first line treatment of physically fit CLL patients without del17p or TP53 mutation 2017 ·(unknown), Jasmin Bahlo, (unknown), (unknown), (unknown), (unknown), Matthias Ritgen, (unknown), S. Stilgenbauer, (unknown), (unknown), Michael Hallek, (unknown)	1
11	Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL 2016 ·Leukemia ·Christian Maurer, Petra Langerbeins, Jasmin Bahlo, Paula Cramer, Anna‐Maria Fink, Natali Pflug, Anja Engelke, Julia von Tresckow, Gábor Kovács, Stephan Stilgenbauer, C-M Wendtner, Lothar Müller, Matthias Ritgen, (unknown), Kirsten Fischer, Michael Hallek, Barbara Eichhorst, (unknown)	35
12	The Role of Minimal Residual Disease Measurements in the Therapy for CLL 2013 ·Hematology/Oncology Clinics of North America ·Sebastian Böttcher, Michael Hallek, Matthias Ritgen, Michael Kneba	36
13	First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia 2009 ·Blood ·Barbara Eichhorst, Raymonde Busch, Stephan Stilgenbauer, Martina Stauch, Manuela A. Bergmann, Matthias Ritgen, N Kranzhöfer, Robert Rohrberg, Ulrike Söling, Oswald Burkhard, Anne Westermann, Valentin Goede, Carmen D. Schweighofer, Kirsten Fischer, Anna‐Maria Fink, Clemens‐Martin Wendtner, Günter Brittinger, Hartmut Döhner, Bertold Emmerich, Michael Hallek, (unknown)	238
14	Evaluation of minimal residual disease in chronic lymphocytic leukemia 2009 ·Matthias Ritgen, Sebastian Böttcher, Peter Dreger, Michael Kneba	0
15	Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma 2009 ·Haematologica ·Inga Nagel, Takashi Akasaka, Wolfram Klapper, Stefan Gesk, Sebastian Böttcher, Matthias Ritgen, Lana Harder, Michael Kneba, Martin J.S. Dyer, Reiner Siebert	15
16	Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial 2008 ·Leukemia ·Matthias Ritgen, Sebastian Böttcher, Stephan Stilgenbauer, Donald Bunjes, J. Schubert, Sandra Cohen, Andreas Humpe, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Peter Dreger, (unknown)	62
17	Reduced expression of C1q-mRNA in monocytes from patients with systemic lupus erythematosus 2006 ·Clinical & Experimental Immunology ·Frank Moosig, Frédérik Damm, (unknown), Matthias Ritgen, Rainald Zeuner, Michael Kneba, Martin Ernst, Johann O. Schröder	24
18	Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease 2005 ·European Journal Of Haematology ·Christiane Pott, Carsten Schrader, Monika Brüggemann, Matthias Ritgen, Lana Harder, Thorsten Raff, Markus Tiemann, Peter Dreger, Michael Kneba	17
19	Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) 2004 ·Leukemia ·C.‐M. Wendtner, Matthias Ritgen, (unknown), Guenter Fingerle-Rowson, Hartmut Campe, Gundula Jäger, Barbara Eichhorst, Robert Busch, Heinz Diem, Andreas Engert, Stephan Stilgenbauer, Hartmut Döhner, Michael Kneba, Bertold Emmerich, Michael Hallek, (unknown)	201
20	Fludarabine induces higher response rates in first line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil Interim analysis of a phase III study of the German CLL Study Group 2003 ·Blood ·Barbara Eichhorst, Raymonde Busch, Martina Stauch, Michael Kneba, Matthias Ritgen, (unknown), Oswald Burkhard, Michael Bergmann, Clemens‐Martin Wendtner, Wolfgang Hiddemann, Bertold Emmerich, Michael Hallek, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact